Clognil is indicated for the reduction of atherosclerotic events like myocardial infarction, stroke and vascular death in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease.
Clognil is contraindicated in patients with a hypersensitivity to the drug substance or any component of the product, and those with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Dosage & Administration
The recommended dose is one tablet once daily.
A very rare case of hypersensitivity reactions of Clognil(Clopidogrel) includes angioedema, bronchospasms andanaphylactoid reactions. The clinical adverse reactions are asGI haemorrhage, agranulocytosis, dyspepsia, gastritis,diarrhoea, rash, palpitation and vomiting.
As with other antiplatelet agents, Clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions. If a patient is to undergo elective surgery and an antiplatelet effect is not desired, Clopidogrel should be discontinued 7 days prior to surgery.
Hepatic or Renal Impairment
Should be avoided in patients with impaired hepatic and renal function.
Aspirin causes sodium and water retention in patients with renal impairment and increases the risk of gastrointestinal bleeding.
Aspirin: Aspirin does not modify the Clognil (Clopidogrel)mediated inhibition of ADP-induced platelet aggregation.
NSAIDs: Concomitant administration of Clognil(Clopidogrel) with naproxen is associated withgastrointestinal blood loss.
Others: No clinically significant pharmacodynamics wereobserved when Clognil (Clopidogrel) was co-administered with atenolol, nifedipine or both atenolol and nifedipine.
Clognil: Each box contains 3x10 tablets in ALU-ALU blister pack.